{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:15Z","timestamp":1791994575826,"version":"4.4.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["2018C04013, 2019PY037"],"award-info":[{"award-number":["2018C04013, 2019PY037"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pemphigus vulgaris (PV) is a kind of IgG-mediated autoimmune blistering disease (AIBD) that is characterized by loss of keratinocyte adhesion in the epithelium of mucous membranes or skin. Recently, pemphigus vulgaris was thought to be associated with classical T helper 2 (T<jats:sub>H2<\/jats:sub>)-type cytokines such as interleukin\u20104 (IL-4) and interleukin\u201017 (IL-17) signaling pathway. A humanized monoclonal IgG4 antibody called dupilumab binds to the alpha subunit of the interleukin\u20104 receptor (IL\u20104R\u03b1) and inhibits the signaling of IL-4 and interleukin\u201013 (IL-13), which has been successfully applied for atopic dermatitis and asthma. Currently, the clinical trial evaluating dupilumab in bullous pemphigoid is ongoing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether dupilumab may be of benefit in the aggressive refractory pemphigus vulgaris.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We report a 35-year old male with refractory pemphigus vulgaris and pulmonary tuberculosis who received treatment with dupilumab for 10 weeks. The mRNA expression of peripheral blood mononuclear cells (PBMCs) was analyzed by RNA sequencing (RNA-seq) which showed the gene expression changes after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The skin lesions of the patient improved in response to the combined use of dupilumab, moderate dose of glucocorticosteroids, and intravenous immune globulin (IVIG). Downregulations of inflammatory response-related genes and IL-17 signaling pathway-related genes were observed in PBMCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We describe a patient with refractory pemphigus vulgaris and pulmonary tuberculosis who had the disease under control with combined use of dupilumab as an add-on treatment. Dupilumab may provide a beneficial effect in aggressive refractory pemphigus vulgaris.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.825796","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T05:37:21Z","timestamp":1644385041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated With Pulmonary Tuberculosis: A Case Report and the RNA-seq Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Siji","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunting","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.008","article-title":"Immunophenotyping in Pemphigus Reveals a TH17\/TFH17 Cell\u2013Dominated Immune Response Promoting Desmoglein1\/3-Specific Autoantibody Production","volume":"147","author":"Holstein","year":"2021","journal-title":"J Allergy Clin Immun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.1.635","article-title":"Dichotomy of Autoreactive Th1 and Th2 Cell Responses to Desmoglein 3 in Patients With Pemphigus Vulgaris (PV) and Healthy Carriers of PV-Associated HLA Class II Alleles","volume":"170","author":"Veldman","year":"2003","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jaci.2020.05.009","article-title":"Mechanisms of Skin Autoimmunity: Cellular and Soluble Immune Components of the Skin","volume":"146","author":"Gudjonsson","year":"2020","journal-title":"J Allergy Clin Immun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a Novel Therapy for Bullous Pemphigoid: A Multicenter Case Series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13190","article-title":"Targeting Interleukin 4 Receptor \u03b1: A New Approach to the Treatment of Cutaneous Autoimmune Bullous Diseases","volume":"33","author":"Russo","year":"2020","journal-title":"Dermatol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.665522","article-title":"Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab","volume":"12","author":"Sinagra","year":"2021","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.11.006","article-title":"Clinical Activity of Pemphigus Vulgaris Relates to IgE Autoantibodies Against Desmoglein 3","volume":"134","author":"Nagel","year":"2010","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: A Fast Spliced Aligner With Low Memory Requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat Methods"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.3.1740","article-title":"A Single Helper T Cell Clone Is Sufficient to Commit Polyclonal Naive B Cells to Produce Pathogenic IgG in Experimental Pemphigus Vulgaris","volume":"182","author":"Takahashi","year":"2009","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401081","article-title":"Pathogenic IgG Antibodies Against Desmoglein 3 in Pemphigus Vulgaris are Regulated by HLA-DRB1*04:02-Restricted T Cells","volume":"193","author":"Eming","year":"2014","journal-title":"J Immunol (Baltimore Md 1950)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.825796\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T05:37:22Z","timestamp":1644385042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.825796\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2022.825796"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.825796","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"article-number":"825796"}}